113. Muscular dystrophy
567 clinical trials,   442 drugs   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02836418
(ClinicalTrials.gov)
July 12, 201630/6/2016Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular DystrophyAn Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular DystrophyFacioscapulohumeral Muscular Dystrophy;Limb Girdle Muscular DystrophyDrug: ATYR1940aTyr Pharma, Inc.NULLCompleted16 Years25 YearsAll8Phase 1;Phase 2United States;Denmark;Italy
2EUCTR2016-000624-25-DK
(EUCTR)
22/06/201619/04/2016An Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular DystrophyAn Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular Dystrophy Limb Girdle Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy
MedDRA version: 19.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: ATYR1940
Product Code: ATYR1940
INN or Proposed INN: Not available yet
Other descriptive name: ATYR1940
aTyr Pharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
22Phase 1;Phase 2United States;Denmark;Italy
3NCT02603562
(ClinicalTrials.gov)
March 30, 20165/11/2015Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular DystrophyAn Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular DystrophyFacioscapulohumeral Muscular Dystrophy (FSHD)Biological: ATYR1940;Biological: PlaceboaTyr Pharma, Inc.NULLCompleted12 Years25 YearsAll8Phase 1;Phase 2United States;France;Italy
4EUCTR2015-001910-88-DK
(EUCTR)
17/12/201530/06/2015A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Muscular DystrophiesAn Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Muscular Dystrophies Limb Girdle Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy
MedDRA version: 19.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: ATYR1940
Product Code: ATYR1940
INN or Proposed INN: Not available yet
aTyr Pharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
16Phase 1;Phase 2France;United States;Denmark;Italy
5NCT02579239
(ClinicalTrials.gov)
November 5, 201528/9/2015The Safety and Biological Activity of ATYR1940 in Patients With Limb Girdle or Facioscapulohumeral Muscular DystrophiesAn Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular DystrophiesLimb-Girdle Muscular Dystrophies;Facioscapulohumeral Muscular DystrophyBiological: ATYR1940;Biological: PlaceboaTyr Pharma, Inc.NULLCompleted18 Years75 YearsAll18Phase 1;Phase 2United States;Denmark;France;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02531217
(ClinicalTrials.gov)
September 201525/6/2015Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study ExtensionAn Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)Facioscapulohumeral Muscular DystrophyBiological: ATYR1940aTyr Pharma, Inc.NULLCompleted18 Years65 YearsAll9Phase 1;Phase 2United States;Italy;Netherlands
7EUCTR2015-001912-36-NL
(EUCTR)
04/08/201522/06/2015A Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Exposure of ATYR1940 in Adult Patients with Genetic MyopathyAn Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) Facioscapulohumeral muscular dystrophy
MedDRA version: 19.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: ATYR1940
Product Code: ATYR1940
INN or Proposed INN: Not available yet
Other descriptive name: ATYR1940
aTyr Pharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
32Phase 1;Phase 2United States;Netherlands;Italy
8EUCTR2014-001753-17-NL
(EUCTR)
19/09/201403/06/2014A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Activity of ATYR1940 in Adults with Genetic MyopathyA Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Defined Genetic Muscular Dystrophies Facioscapulohumeral muscular dystrophy
MedDRA version: 17.1;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: ATYR1940
Product Code: ATYR1940
INN or Proposed INN: N/A
aTyr Pharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
44France;United States;Netherlands;Italy
9NCT02239224
(ClinicalTrials.gov)
August 20147/9/2014Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients With Muscular DystrophyA Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Biological Activity of ATYR1940 in Adult Patients With Molecularly Defined Genetic Muscular DystrophiesFacioscapulohumeral Muscular Dystrophy (FSHD)Biological: Placebo;Biological: ATYR1940aTyr Pharma, Inc.NULLCompleted18 Years65 YearsAll20Phase 1;Phase 2United States;France;Italy;Netherlands
10EUCTR2014-001753-17-IT
(EUCTR)
30/07/201413/06/2014A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Activity of ATYR1940 in Adults with Genetic MyopathyA Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Defined Genetic Muscular Dystrophies Facioscapulohumeral muscular dystrophy
MedDRA version: 17.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: ATYR1940
Product Code: ATYR1940
INN or Proposed INN: N/A
aTyr Pharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
44France;United States;Netherlands;Italy